Cutiss AG

Our solution –
Personalized, bio-engineered, dermo-epidermal skin grafts

After more than 15 years of research (Tissue Biology Research Unit, University Children’s Hospital Zurich), CUTISS AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin™, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin™ is expected to result in a minimally scarring outcome after transplantation. denovoSkin™ received a Swissmedic, EMA and FDA Orphan drug designation for the treatment of burns.

Cutiss AG

Our solution –
Personalized, bio-engineered, dermo-epidermal skin grafts

After more than 15 years of research (Tissue Biology Research Unit, University Children’s Hospital Zurich), CUTISS AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin™, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin™ is expected to result in a minimally scarring outcome after transplantation. denovoSkin™ received a Swissmedic, EMA and FDA Orphan drug designation for the treatment of burns.

Cutiss AG

Technology

To bio-engineer denovoSkin™, a small biopsy of healthy skin is harvested from the patient. The biopsy is processed to isolate epidermal and dermal cells. The cells are expanded in vitro, and thereafter used in combination with a hydrogel to create a dermo-epidermal skin graft. denovoSkin™ is now ready to be transplanted on the patient’s wounds. The safety trials for denovoSkin™ have been completed. The efficacy trials are supported by Wyss Zurich.

©Susanne Staubli University Children's Hospital Zurich
@Susanne Staubli University Children's Hospital Zurich
Cutiss AG

Potential

denovoSkin™ has a large potential. It could be of great benefit for patients with burns, traumas, that undergo reconstructive or plastic procedures, as well as for patients with chronic ulcers or congenital malformations that lead to skin-related problems.

denovoSkin™ is a patented, personalized, autologous bio-engineered human skin graft classified as Advanced Therapy Medicinal Product (ATMP). It is engineered in large quantities starting-off from a stamp-sized skin biopsy of the patient, thus solving the donor site shortage issue. Moreover, because of its dermo-epidermal structure, denovoSkin™ leads to minimal scarring after transplantation.

Its outstanding performance could considerably reduce or even avoids further corrective interventions, allowing for considerable savings. denovoSkin™ is also granted with Orphan Drug Designation for the treatment of burns by Swissmedic, EMA and FDA.

©Wyss Zurich
©WyssZurich
Cutiss AG

Get involved

Every year, major burns or a large skin graft have a huge impact on the lives of millions of patients, children and their loved ones. In fact, the standard of care is scarce and still leads to frequent scarring. CUTISS AG wants to offer the best possible skin replacement, denovoSkin™: a safe, effective, accessible and lasting treatment of the skin tissue.

Our vision is great, but our journey is challenging! The trust, support and commitment of many people is needed to succeed! In order to be able to carry out our clinical studies and, at the same time, drive research forward, we also depend on large financial resources. If you are interested in investing as a potential investor in our work, please visit our dedicated subsite with more information.

You can also support our research and clinical programs with a donation. Please directly contact the following IBAN to make a contribution: Zürcher Kantonalbank, 8010 Zürich IBAN CH02 0700 0110 0065 8561 4 (for all donations a confirmation will be issued)

Join us on our exciting journey and help us change the lives of burn victims! Thank you so much!

©CUTISS AG
©CUTISS AG
Scroll to Top

Newsletter

Would you like to contact us as a journalist?

This website uses cookies to ensure you get the best experience on our website.